2 September 2010

Private Equity Investor

BUY

10/07/2003

Private Equity Investor is an unique investment vehicle which raised £100m at the height of the tech bubble in February 2000. This cash was committed to 18 top-performing US venture capital funds to invest. After three years, two thirds of the money has been drawn down but the bear market has meant the uncommitted cash, parked in bonds, has outperformed the venture capital investments made so far. This approach has also protected the company's net asset value to a certain extent, restricting its fall since launch to 25.9% leaving it at 143.6p per share at the end of March. Chairman Barbara Thomas has now prudently called the top of the bond market and switched the group's fixed income portfolio into a bespoke fund of hedge funds. Over the past year, net asset value fell 21.4%, but the shares fell even further, sliding 29.4% to 87.5p, putting them at a 39% discount to net assets. Some £35m, or 70p a share, remains uninvested, meaning the £37.8m venture capital portfolio is valued at only £13.5m, or 27p a share. This seems unfair, particularly as some investments, such as in Internet travel agent Expedia, are being realised. Since the year-end active investor Laxey Partners has built up a 11.7% stake in the company, noticing the extreme value. The shares have risen 9.5p but still stand at a 32.5% discount. Investors should follow Laxey's lead and take advantage of this.

Sector: General Financial

Companies: Private Equity Investor

Market cap: £48.5m

PE Forecast: n/a

Share price: 97p

Subscribe today


More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.

Subscribe today and save 50%

VCT Report 2010

VCT Report 2010 uncovers the money available

for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted

company.

Order VCT Report 2010 today using this online form

Cash Shells Directory 2010

A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.

Coverage of AIM, techMARK and PLUS Markets

Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.

Take control of your investments

A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.

The Financial Times Guide to Personal Tax

is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.

The AIM Guide Spring 2010

The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).

A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!

Share recommendations and small-cap stock picks

Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.

Popular Recommendations

Latest Recommendations

Delcam 01/09/2010

Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.

Antisoma 01/09/2010

Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.

GW Pharmaceuticals 31/08/2010

GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.

More Recommendations

Sectors

Vitesse Media Events